Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma; Zgura Anca; Oana Gabriela Trifănescu; Laurenția Nicoleta Galeș; Antonia Ruxandra Folea; Loredana Stanca; Liviu Bîlteanu; Rodica M. Anghel

doi:10.12659/MSM.941754

20 September 2023 : Clinical Research

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma^{^A Study design/planning

^B Data collection/entry

^C Data analysis/statistics

^G Funds collection

" data-author="4365589">12ABCG}, Zgura Anca^1E, Oana Gabriela Trifănescu^{^A Study design/planning

" data-author="4365591">12A}, Laurenția Nicoleta Galeș^{^D Data interpretation

^*Corresponding author: [email protected]
^*Corresponding author: [email protected]
" data-author="4365592">12D*}, Antonia Ruxandra Folea^{^C Data analysis/statistics

^D Data interpretation

^E Preparation of manuscript

^F Literature analysis/search

" data-author="4365593">2CDEF}, Loredana Stanca^3B, Liviu Bîlteanu^{³Department of Preclinical Science, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, Bucharest, Romania
⁴Laboratory of Molecular Nanotechnologies, National Institute for Research and Development in Microtechnologies, Voluntary, Romania

^A Study design/planning

^B Data collection/entry

^C Data analysis/statistics

^D Data interpretation

^E Preparation of manuscript

^F Literature analysis/search

" data-author="4365595">234ABCDEF}, Rodica M. Anghel^1A

DOI: 10.12659/MSM.941754

Med Sci Monit 2023; 29:e941754

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Supplementary Table 14 The period (in days) from the start of therapy (CHT – chemotherapy, RT – radiotherapy, TT – targeted therapy) to the time of recording the worsening or the emergence of the diastolic dysfunction through delayed relaxation (DDDR), murmurs and valvular heart disease (MVHD), cardiomyopathies and left ventricular conditions (CLVC), great vessels diseases (GVD) and pericardial disease (PD).

		DDDR				MVHD
		CHT	TT	RT		CHT	TT	RT

Mean		330.2	339.0	299.5		288.2	334.9	270.0
SE Mean		67.8	71.1	108.9		58.8	68.5	91.8
Median		221	260	252		241	293	164
SD		279.6	256.4	266.7		242.4	227.1	243.0
Variance		78201.7	65726.2	71144.3		58746.2	51562.3	59043.7
Range		796	725	650		808	649	651
Minimum		61	42	13		2	11	12
Maximum		857	767	663		810	660	663
Percentiles	25	105.0	123.0	43.0		97.5	137.0	142.0
	33	135.6	137.0	97.3		122.4	138.9	155.4
	50	221.0	260.0	252.0		241.0	293.0	164.0
	67	434.3	447.2	484.6		377.5	533.1	319.5
	75	520.5	621.5	588.8		404.5	583.0	564.0



Mean		352.2	213.3	162.8	292.0	352.5	29	131
SE Mean		47.3	49.9	54.3	138.8	259.5
Median		403	163.5	154	183	352.5	29	131
SD		142.0	141.1	108.7	277.6	367.0
Variance		20159.4	19908.5	11810.3	77048.0	134680.5
Range		394	360	205	606	519
Minimum		130	42	69	98	93
Maximum		524	402	274	704	612
Percentiles	25	214.0	105.0	69.3	119.0	93.0
	33	241.3	105.0	69.7	152.6	93.0
	50	403.0	163.5	154.0	183.0	352.5
	67	460.4	342.3	250.6	366.0	.
	75	481.5	373.3	265.0	574.0	.

Back to the Article

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Your Privacy